Thymosin β-4.

Promoting new blood-vessel formation, cell migration, and repair signalling.

Wound healing proceeds through overlapping phases: haemostasis, inflammation, proliferation, and remodelling. Angiogenesis, the growth of new capillaries from existing vessels, is essential to the proliferative phase because new tissue cannot be built or sustained without perfusion. It is driven largely by vascular endothelial growth factor acting on VEGFR2 on endothelial cells, with nitric oxide serving as a downstream and permissive signal that governs vessel dilation, endothelial survival, and sprouting. Cell migration is the other requirement: keratinocytes, fibroblasts, and endothelial cells must physically move into the wound bed, which depends on rapid reorganisation of the actin cytoskeleton. Compounds grouped here engage different points in that sequence. One acts most consistently through the nitric oxide system, promoting endothelial nitric oxide production, with protective effects that are blunted when nitric oxide synthase is blocked. It has been reported to activate a signalling chain involving Src, caveolin-1, and endothelial nitric oxide synthase, and to enhance VEGFR2-driven signalling, which is the proposed basis for its pro-angiogenic effects. It also has reported effects on gut mucosal protection and on tendon fibroblast behaviour. Others derive from a naturally occurring intracellular protein whose best-characterised function is binding monomeric actin in a one-to-one complex. By buffering the pool of unpolymerised actin, it modulates cytoskeletal assembly and therefore cell shape and motility. A short conserved motif within the protein has been reported to promote keratinocyte and endothelial migration, angiogenesis, and anti-inflammatory and anti-apoptotic effects in preclinical models. The relationship between the full protein and the fragment sold under a separate name is a frequent source of confusion, since they are related but not identical entities. This is a pathway where the gap between mechanism and proof is unusually wide, and it deserves plain statement. The molecular actions above are documented, but overwhelmingly in cell culture and rodent models of injury. Controlled human trials are sparse to absent for these compounds, none is an approved medicine for tissue repair in major jurisdictions, and material sold under these names is unregulated with uncertain identity and purity. Promoting angiogenesis is also not universally desirable, since the same signals that build capillaries into healing tissue could in principle support other proliferating tissue, and that question has not been addressed in humans.

Shifting immune-cell behaviour and cytokine balance rather than simply stimulating immunity.

The immune system is regulated rather than merely switched on or off, and the compounds here act as modulators: they can raise responsiveness in a suppressed state and dampen it in an overactive one, which is a different pharmacological category from a stimulant. The relevant machinery includes pattern-recognition receptors such as the Toll-like receptor family on dendritic cells and macrophages, the transcription factor NF-kB that governs pro-inflammatory gene expression, and the balance between T-helper subsets and regulatory T cells that determines the character of an immune response. One compound in this group is a thymus-derived peptide that acts principally through Toll-like receptors 2 and 9 on antigen-presenting cells. Downstream MyD88-dependent signalling promotes dendritic cell maturation, biases naive T cells toward a Th1 pattern, and augments natural killer and cytotoxic T cell activity, while also engaging regulatory pathways. Its usefulness is described in settings of immune exhaustion rather than in healthy immunity. A second acts largely without classical receptor engagement. It is taken into intestinal epithelial and immune cells by a proton-coupled di- and tripeptide transporter that is normally restricted to the small intestine but becomes induced in the colon during inflammation, meaning uptake is greatest precisely where inflammation is present. Once inside, it inhibits NF-kB and MAP kinase signalling, reducing pro-inflammatory cytokine output. A third is a widely distributed neuropeptide signalling through two class B G-protein-coupled receptors that raise cyclic AMP. Alongside smooth-muscle relaxation and secretory effects, it produces broad anti-inflammatory action by shifting cytokine balance away from pro-inflammatory mediators and supporting regulatory T cell populations. A fourth is included for its anti-inflammatory and anti-apoptotic effects, which accompany its better-known role in cytoskeletal regulation. Evidence quality varies considerably across this group and should not be averaged. One member is an approved medicine in a number of countries for specific infectious and immunological indications, giving it genuine human clinical grounding. Others rest largely on cell and animal work, with human data limited or confined to small studies. Immune modulation also carries a bidirectional risk that is rarely acknowledged: a compound capable of enhancing immune activity is in principle capable of aggravating autoimmune conditions, and that interaction is poorly characterised for most of this group.

The full-length peptide reached controlled ophthalmic trials; the systemic injectable uses have no comparable evidence.

Repair signals come from animal cardiac, dermal and corneal models rather than human outcome trials.

Cardiac repair findings are mouse work; no human cardiac outcome trial has confirmed them.

Material sold as TB-500 is generally a fragment or analog, not verified full-length thymosin beta-4.

Controlled safety data cover eye-drop use; injectable exposure has no characterized human safety profile.